ambisome 50mg vial powder for solution for infusion
gilead sciences limited - amphotericin b - powder for solution for infusion - 50 mg
amphon -b 50 mg injection
opsonin pharma limited - amphotericin b - injection - 50 mg/vial
inj. amfy-50mg injection
intas pharmaceuticals ltd chinubhai centre off. nehru bridge ashram road - amphotericin - injection - amphotericin 50mg - antimycotics for systemic use: antibiotics
flucasten one
teva pharma (new zealand) limited - fluconazole 150mg - capsule - 150 mg - active: fluconazole 150mg excipient: colloidal silicon dioxide gelatin lactose magnesium stearate maize starch methyl hydroxybenzoate patent blue v propyl hydroxybenzoate purified water sodium laurilsulfate titanium dioxide - flucasten one 150 mg, given orally, is indicated for vaginal candidiasis.
fluconazole
viatris limited - fluconazole 150mg; fluconazole 150mg - capsule - 150 mg - active: fluconazole 150mg excipient: gelatin hydrated silica lactose monohydrate magnesium stearate pregelatinised maize starch sodium laurilsulfate tekprint black sw-9008 titanium dioxide active: fluconazole 150mg excipient: gelatin hydrated silica lactose monohydrate magnesium stearate maize starch sodium laurilsulfate tekprint black sw-9008 titanium dioxide - 1. cryptococcosis, including cryptococcal meningitis and infections of other sites (e.g. pulmonary, cutaneous). normal hosts, and patients with aids, organ transplants or other causes of immunosuppression may be treated. fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal disease in patients with aids. 2. systemic candidiasis including candidaemia, disseminated candidiasis and other forms of invasive candidal infection including infections of the peritoneum, endocardium and pulmonary and urinary tracts. patients with malignancy, in intensive care units, receiving cytotoxic or immunosuppressive therapy, or with other factors predisposing to candidal infection may be treated. 3. mucosal candidiasis. these include oropharyngeal, oesophageal, non-invasive bronchopulmonary infections, candiduria, mucocutaneous and chronic oral atrophic candidiasis (denture sore mouth). normal hosts and patients with compromised immune function may be treated. 4. vaginal candidiasis, acute or recurrent. 5. prevention of fungal infection in immunocompromised patients considered at risk as a consequence of hiv infections or neutropenia following cytotoxic chemotherapy, radiotherapy or bone marrow transplant 6. fluconazole 50 mg & 150 mg capsules are also indicated for the treatment of dermatomycoses including tinea pedis, tinea corporis, tinea cruris, pityriasis versicolor & candidiasis.
fluconazole
viatris limited - fluconazole 50mg; fluconazole 50mg; fluconazole 50mg - capsule - 50 mg - active: fluconazole 50mg excipient: erythrosine gelatin hydrated silica lactose monohydrate magnesium stearate patent blue v pregelatinised maize starch sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9009 titanium dioxide active: fluconazole 50mg excipient: erythrosine gelatin hydrated silica lactose monohydrate magnesium stearate maize starch patent blue v sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9009 titanium dioxide active: fluconazole 50mg excipient: gelatin hydrated silica lactose monohydrate magnesium stearate maize starch patent blue v ponceau 4r sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9009 titanium dioxide - 1. cryptococcosis, including cryptococcal meningitis and infections of other sites (e.g. pulmonary, cutaneous). normal hosts, and patients with aids, organ transplants or other causes of immunosuppression may be treated. fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal disease in patients with aids. 2. systemic candidiasis including candidaemia, disseminated candidiasis and other forms of invasive candidal infection including infections of the peritoneum, endocardium and pulmonary and urinary tracts. patients with malignancy, in intensive care units, receiving cytotoxic or immunosuppressive therapy, or with other factors predisposing to candidal infection may be treated. 3. mucosal candidiasis. these include oropharyngeal, oesophageal, non-invasive bronchopulmonary infections, candiduria, mucocutaneous and chronic oral atrophic candidiasis (denture sore mouth). normal hosts and patients with compromised immune function may be treated. 4. vaginal candidiasis, acute or recurrent. 5. prevention of fungal infection in immunocompromised patients considered at risk as a consequence of hiv infections or neutropenia following cytotoxic chemotherapy, radiotherapy or bone marrow transplant 6. fluconazole 50 mg & 150 mg capsules are also indicated for the treatment of dermatomycoses including tinea pedis, tinea corporis, tinea cruris, pityriasis versicolor & candidiasis.
ozole
douglas pharmaceuticals limited - fluconazole 150mg - capsule - 150 mg - active: fluconazole 150mg excipient: ammonia solution butyl alcohol colloidal silicon dioxide ethanol gelatin iron oxide black isopropyl alcohol lactose monohydrate magnesium stearate maize starch patent blue v potassium hydroxide propylene glycol purified water shellac sodium laurilsulfate titanium dioxide water - ozole 150 mg capsule, given orally, is indicated for vaginal candidiasis.
ozole
douglas pharmaceuticals limited - fluconazole 50mg - capsule - 50 mg - active: fluconazole 50mg excipient: ammonia solution butyl alcohol colloidal silicon dioxide ethanol gelatin iron oxide black isopropyl alcohol lactose monohydrate magnesium stearate maize starch patent blue v potassium hydroxide propylene glycol purified water shellac sodium laurilsulfate titanium dioxide water - ozole is indicated for the treatment of the following conditions: 1. cryptococcosis, including cryptococcal meningitis and infections of other sites (e.g. pulmonary cutaneous). normal hosts, and patients with aids, organ transplants or other causes of immunosuppression may be treated. ozole can be used as maintenance therapy to prevent relapse of cryptococcal disease in patients with aids. 2. systemic candidiasis including candidaemia, disseninated candidasis and other forms of invasive candidal infection, including infections of the peritoneum, endocardium and pulmonary and urinary tracts. patients with malignancy, in intensive care units, receiving cytotoxic or immunosuppressive therapy, or with other factors predisposing to candidal infection may be treated. 3. mucosal candidiasis. these include oropharyngeal, oesophageal, non-invasive bronchopulmonary infections, candiduria, mucocutaneous and chronic oral atrophic candidiasis (denture sore mouth). normal hosts and patients with compromised immune function may be treated. 4. vaginal candidiasis, acute or recurrent. 5. prevention of fungal infection in immunocompromised patients considered at risk as a consequence of hiv infections or neutropenia following cytoxic chemotherapy, radiotherapy or bone marrow transplant. 6. ozole 50 mg and 150 mg capsules are also indicated for the treatment of dermatomycoses including tinea pedis, tinea corporis, tinea cruris, pityriasis versicolor & candidiasis.
mycamine
seqirus (nz) ltd - micafungin 50mg - powder for injection - 50 mg - active: micafungin 50mg excipient: citric acid lactose nitrogen sodium hydroxide - treatment of invasive candidiasis in children & adults treatment of oesophageal candidiasis in adults, adolescents nlt 16 yrs of age, and elderly patients for whom intravenous therapy is appropriate prophylaxis of candida infection in children and adult patients undergoing allogenic haematopoietic stem cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count below 500 cells per microliter) for 10 or more days
sulprix
viatris limited - amisulpride 50mg - tablet - 50 mg - active: amisulpride 50mg excipient: hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose sodium starch glycolate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.